* ESCAgenetics Corp., of San Carlos, Calif., has been deleted fromthe American Stock Exchange for failure to meet financial andoperational guidelines. ESCAgenetics now is being traded on theElectronic Bulletin Board under the symbol, ESNG.
* Vical Inc., of San Diego, said Phase I/II trials of its anti-cancerdrug, Allovectin-7, showed it was safe and that the productsuccessfully transferred to tumor lesions a gene that encodes amismatched transplantation antigen, HLA-B7. The treatment isdesigned to trigger an immune system attack against the foreignantigen and destroy the tumor cells. Vical said the data revealed"measurable tumor shrinkage" in a portion of the patients withadvanced melanoma. Forty patients with colorectal and renal cancers,in addition to melanoma, participated in the studies.
* British Biotech plc., of Oxford, England, said data from Phase Itrials of its oral cancer drug, BB-2516, revealed it was safe and wasabsorbed into the blood streams of healthy volunteers. The compoundis a matrix metalloproteinase inhibitor. Efficacy studies are plannedfor patients with ovarian, colorectal, prostate, pancreatic and lungcancers.
* ImClone Systems Inc., of New York, said preclinical studies of itsanti-flk-1 monoclonal antibody, DC101, showed the drug suppressedthe growth of human gliobastomal tumors in an animal model.DC101 targets angiogenesis by blocking the receptor flk-1 found onthe vascular endothelial cells of tumors. Activation of flk-1 byvascular endothelial growth factor is believed to stimulatedevelopment of blood vessels needed for tumor growth.
* ImmunoGen Inc., of Cambridge, Mass., and Oxford MolecularGroup, of Oxford, England, cross-licensed rights to technologiesinvolved in humanized monoclonal antibodies. The deal givesImmunoGen access to Oxford Molecular's antibody computermodeling software and Oxford Molecular received rights toImmunoGen's "resurfacing" method of creating humanizedmonoclonal antibodies.
* SmithKline Beecham Corp., of Philadelphia, said it received itsfirst marketing approval of Infanrix in Germany for primaryvaccination. Infanrix is a combined diphtheria, tetanus and acellularpertussis vaccine. It differs from other diphtheria, tetanus andpertussis vaccines in that it is not based on whole-cell pertussis,which has been associated with adverse side effects.
* AMDL Inc., of Tustin, Calif., closed a private placement of sharesand warrants that could bring in total proceeds of $625,000.
* Arris Pharmaceuticals Corp., of South San Francisco, started PhaseI-B multiple dose tolerance study of APC 366, a tryptase inhibitor forasthma.
* Biomatrix Inc., of Ridgefield, N.J., signed a distribution agreementfor Italy with Recordati Industria Chimca e Farmaceutica S.p.A. tomarket Synvisc for osteoarthritis. Also, Biomatrix received approvalto market Synvisc in Sweden.
* Chemex Pharmaceuticals Inc., of Fort Lee, N.J., and the BlockDrug Co., of Jersey City, N.J., ended their joint venture in the area ofdermatology. All products, except Amlexanox, will be owned solelyby Chemex.
* Gliatech Inc., of Cleveland, was awarded a $100,000 SmallBusiness Innovation Research grant to develop products to treatattention deficit disorders.
* Immunomedics Inc., of Morris Plains, N.J., and MallinckrodtGroup Inc., of St. Louis, signed a license agreement in whichMallinckrodt will market CEA-Scan, an in vivo imaging product, inWestern Europe and some Eastern European countries. Also,Immunomedics received a $100,000 Small Business InnovationResearch grant to study a humanized lymphoma-targeting antibody.
* Lidak Pharmaceuticals Inc., of La Jolla, Calif., said it completedtreating patients in a Phase III trial of Lidakol for recurrent herpes inEurope. Results were not yet available.
* Mycogen Inc., of San Diego, received approval to produce plantingseeds for corn hybrids that are genetically engineered to resist insectdamage.
* Neurobiological Technologies Inc., of Richmond, Calif., initiated aPhase I/II trial of corticotropin-releasing factor for acute asthma.
* Paracelsian Inc., of Ithaca, N.Y., obtained seven anti-cancercompounds, isolated from herbs and fungi, from two researchinstitutions in China.
* Pharmacyclics Inc., of Sunnyvale, Calif., entered into acollaboration with Burroughs Wellcome Co., of Research TrianglePark, N.C., for the production of the contrast agent, Gadolite oralsuspension.
(c) 1997 American Health Consultants. All rights reserved.